Product Name:5-methylquinazolin-4(1H)-one

IUPAC Name:5-methyl-1,4-dihydroquinazolin-4-one

CAS:75844-41-6
Molecular Formula:C9H8N2O
Purity:95%
Catalog Number:CM128372
Molecular Weight:160.18

Packing Unit Available Stock Price($) Quantity
CM128372-1g in stock ƿƥŹ
CM128372-5g in stock ŗƓů

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:75844-41-6
Molecular Formula:C9H8N2O
Melting Point:-
Smiles Code:O=C1N=CNC2=C1C(C)=CC=C2
Density:
Catalog Number:CM128372
Molecular Weight:160.18
Boiling Point:330.027°C at 760 mmHg
MDL No:MFCD08436076
Storage:Keep in dark place, store at room temperature.

Category Infos

Quinazolines
Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

Column Infos

Tinlorafenib
The Journal of Medicinal Chemistry releases an article titled "Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer". Mutations in the BRAF gene result in MAPK pathway activation that are most commonly found in human melanomas. The BRAF V600E mutation is among the most frequent types. Present BRAF inhibitors have significantly improved treatment outcomes for patients with BRAF V600-mutant cancers. However, their effectiveness is limited by disease progression in the brain as they don’t adequately penetrate the blood-brain barrier (BBB).
Pfizer’s Tinlorafenib (formerly PF 07284890) is a highly brain-penetrant inhibitor of BRAF V600-mutant tumors, and currently in a phase 1 clinical trial (NCT04543188).